• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Philips touts Stellarex drug-coated balloon data

May 30, 2019 By Danielle Kirsh

philips-stellarex-low-dose-drug-coated-balloonPatients using Royal Philips’s (NYSE:PHG) Stellarex drug-coated balloon maintained blood flow through the treated segment of diseased arteries at three years in a pair of clinical trials.

Stellarex is designed to restore and maintain blood flow in the superficial femoral artery and peripheral arteries. It’s coated using the company’s EnduraCoat technology to elute the drug paclitaxel. Spectranetics won FDA pre-market approval for the device in 2017, before being acquired by Royal Philips later that year.

Three-year results from the Illumenate pivotal trial showed that 64.2% of patients treated with Stellarex were able to maintain blood flow through the treated segment of the diseased artery, compared to only 51% of people treated with an uncoated balloon. The randomized trial included patients with the highest rates of comorbidities like diabetes and renal insufficiency; 43.9% had severely calcified lesions, Philips said.

A second Illumenate European randomized clinical trial showed that, at 36 months, 67.5% of Stellarex-treated patients maintained blood flow, compared to 59.9% in the uncoated balloon group.

“The three-year data of the Illumenate pivotal trial and the Illumenate EU RCT add to the robust and consistent multi-year data of the Stellarex program,” Dr. Jay Mathews, who presented the data, said in a press release. “The demonstrated durability of Stellarex in the complex patient pool of the Illumenate pivotal trial, which are patients that are at high risk for restenosis, a recurring blockage, is unique in the industry. Moreover, we continue to see no significant difference in mortality rates between patients treated with Stellarex and those treated with uncoated balloons, which confirms our confidence in the safety profile of Stellarex.”

Both studies showed no significant difference in mortality compared to uncoated balloon treatment. The Stellarex arm had a mortality rate of 10.1% in the Illumenate pivotal, compared to 11% for patients treated with an uncoated balloon. The European study’s mortality rate was 9.4% for Stellarex patients, compared with 8.5% for uncoated balloon patients.

“We are committed to providing clinically proven image-guided therapy solutions that enhance the procedure and positively impact patient outcomes,” added image-guided therapy chief business leader Bert van Meurs. “Stellarex is the only low-dose drug-coated balloon with a proven treatment effect at three years compared to the existing standard-of-care in the U.S. and Europe. The combination with our interventional imaging systems, such as the successful Azurion platform, our recently-introduced IntraSight intravascular diagnostic application platform, and associated services, enables clinicians to decide, guide, treat and confirm the appropriate peripheral vascular treatment.”

Filed Under: Big Data, Clinical Trials, Vascular Tagged With: Royal Philips

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS